News

Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward ...
Oncocyte Corporation: Oncocyte Reports Q1 2025 Results and Business Progress
Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are ...
Oncocyte Reports Q1 2025 Results and Business Progress
IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first ...